FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE...

FORM 8-K​

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 31, 2015​

​

	Column 1	Column 2
0	Item 1.01.	Entry into a Material Definitive Agreement.

On December 31, 2015, Unilife Corporation (the “Company” or “we”) entered into an exclusivity agreement (the “Agreement”) with Amgen Inc. (the “Counterparty”). The Agreement was entered into in connection with the previously announced review by the Company of potential strategic alternatives, including a strategic partnership with one or more parties or the licensing of some of the Company’s proprietary technologies (a “Potential Transaction”). Pursuant to the Agreement, we agreed to negotiate a Potential Transaction exclusively with the Counterparty until the earlier of January 31, 2016 or the Counterparty notifies us in writing that it has ceased to consider a Potential Transaction (the “Exclusivity Period”). Accordingly, the Company has ceased negotiations with all other parties that had expressed an interest in a Potential Transaction with the Company.
Pursuant to the Agreement, the Counterparty paid to the Company a non-refundable $15 million deposit (the “Deposit”) as consideration for the following non-exclusive and exclusive rights and licenses provided for in the Agreement:

----

The Form 8-K was dated 31st December therefore the $15m was received on or before December 31st from Amgen as a customer

Appendix 4 C is a cash flow statement and therefore would not reflect 1) Sales in Q2 which would not be paid for until Q3 ,and 2) sales in Q2 that might have been paid for by previous deposits.